DHS - ETF AI Analysis
Top Page
WisdomTree U.S. High Dividend Fund (DHS)
Rating:71Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The fund’s year-to-date and recent three-month returns have been strong, showing solid momentum in its strategy.
High-Quality Top Holdings
Several of the largest positions, including major health care, energy, and technology companies, have delivered strong gains, supporting the ETF’s overall results.
Broad Sector Diversification
The ETF spreads its investments across many sectors such as financials, health care, consumer defensive, energy, and utilities, which helps reduce the impact of weakness in any single industry.
Negative Factors
Single-Country Concentration
Almost all assets are invested in U.S. companies, which means the fund is heavily exposed to the U.S. economy and market conditions.
Mixed Performance Among Top Holdings
While many top positions have performed well, some holdings like AT&T have shown weaker results, which can drag on the fund’s overall performance.
Moderate Expense Ratio
The fund’s expense ratio is not extremely high but is also not among the lowest, so fees may slightly reduce long-term returns compared with cheaper alternatives.
DHS vs. SPDR S&P 500 ETF (SPY)
AUM1.57B
RegionNorth America
Expense Ratio0.38%
Beta0.42
IssuerWisdomTree
Inception DateJun 16, 2006
Dividend Yield3.19%
Asset ClassEquity
Index TrackedWisdomTree U.S. High Dividend Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume45,388
30 Day Avg. Volume26,206
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
127.81Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering320
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DHS Summary
DHS is the WisdomTree U.S. High Dividend Fund, an ETF that follows the WisdomTree U.S. High Dividend Index. It focuses on U.S. companies that pay higher-than-average dividends, aiming to provide steady income. The fund owns well-known names like AbbVie, Merck, Exxon Mobil, and AT&T, and spreads investments across sectors such as financials, health care, energy, and utilities. Someone might invest in DHS to add income and diversification to their portfolio, especially if they like dividend-paying stocks. A key risk is that dividend stocks and the ETF’s value can still go up and down with the overall stock market.
How much will it cost me?The WisdomTree U.S. High Dividend Fund (DHS) has an expense ratio of 0.38%, meaning you’ll pay $3.80 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed to focus on high dividend-paying stocks, which requires more research and management. It’s designed for investors seeking income and stability through dividends.
What would affect this ETF?The WisdomTree U.S. High Dividend Fund (DHS) could benefit from stable or rising interest in dividend-paying stocks, especially during periods of economic uncertainty when investors seek reliable income sources. However, it may face challenges if interest rates rise significantly, as higher yields on bonds could make dividend-focused investments less attractive. Additionally, its heavy exposure to sectors like Health Care and Energy means it could be impacted by regulatory changes or fluctuations in commodity prices.
DHS Top 10 Holdings
DHS leans heavily on U.S. health care and tobacco giants, with AbbVie, Merck, Altria, and Philip Morris doing much of the heavy lifting thanks to rising or steady share prices and rich dividends. Energy names like Exxon Mobil and Chevron add extra fuel, recently climbing on stronger commodity trends. Texas Instruments brings a touch of tech flair with a strong year so far, while telecom staples AT&T and Verizon have been more mixed, occasionally dragging on returns. Overall, it’s a U.S.-centric, income-first portfolio anchored in defensive, dividend-heavy sectors.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AbbVie | 4.83% | $75.54M | $443.36B | 28.54% | 66 Neutral | |
| Merck & Company | 4.24% | $66.27M | $321.57B | 64.21% | 80 Outperform | |
| Exxon Mobil | 3.54% | $55.35M | $644.21B | 41.77% | 74 Outperform | |
| Altria Group | 3.54% | $55.34M | $114.09B | 10.60% | 64 Neutral | |
| Philip Morris | 3.27% | $51.15M | $297.41B | 17.10% | 61 Neutral | |
| Texas Instruments | 3.11% | $48.59M | $251.82B | 52.46% | 78 Outperform | |
| AT&T | 2.86% | $44.75M | $159.32B | -16.22% | 71 Outperform | |
| Verizon | 2.66% | $41.54M | $195.46B | 9.16% | 81 Outperform | |
| Bristol-Myers Squibb | 2.58% | $40.35M | $133.41B | 47.66% | 78 Outperform | |
| Chevron | 2.57% | $40.23M | $392.01B | 30.01% | 71 Outperform |
DHS Technical Analysis
Positive
―
Price Trends
113.67
Positive
111.01
Positive
106.62
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DHS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 115.92, equal to the 50-day MA of 113.67, and equal to the 200-day MA of 106.62, indicating a bullish trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DHS.
DHS Peer Comparison
Comparison Results
Performance Comparison
DHS
WisdomTree U.S. High Dividend Fund
116.59
22.60
24.05%
SPYD
SPDR Portfolio S&P 500 High Dividend ETF
―
―
―
FVD
First Trust Value Line Dividend Index Fund
―
―
―
FDL
First Trust Morningstar Dividend Leaders Index Fund
―
―
―
RDIV
Invesco S&P Ultra Dividend Revenue ETF
―
―
―
PEY
Invesco High Yield Equity Dividend Achievers ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents